...
首页> 外文期刊>Current pharmaceutical design >Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs.
【24h】

Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs.

机译:选择性和非选择性非甾体抗炎药的胃肠道作用。

获取原文
获取原文并翻译 | 示例

摘要

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors, which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
机译:非甾体抗炎药(NSAIDs)是最常用的处方药。接受NSAID的患者经常会出现腹部不适,其中一些会出现严重的胃肠道并发症,例如溃疡,出血,穿孔或阻塞。 NSAID的胃肠道副作用主要归因于环氧合酶(COX)的抑制,导致胃粘膜中前列腺素的减少。局部刺激作用也有助于抑制前列腺素的全身作用。 NSAID的抗炎作用是由COX-2抑制介导的,而COX-1抑制则是胃前列腺素的抑制作用。非甾体抗炎药胃肠道并发症的管理费用很高。为了预防或治疗NSAID的胃肠道并发症,可以同时使用抗溃疡药。其他替代方法是使用或替代COX-2选择性抑制剂,该抑制剂可避免胃粘膜前列腺素的合成,并且不会损害胃粘膜。如果患者没有任何风险因素,包括高龄,并发消化性溃疡的病史,并发抗凝药和皮质类固醇药物治疗,那么将COX-2选择性抑制剂作为关节炎疾病的一线治疗药物可能并不划算。在有危险因素的患者或在NSAID治疗过程中出现胃肠道并发症的患者,必要时可以用COX-2选择性抑制剂治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号